MX2022001535A - Uso de sepiapterina y metabolitos de los mismos para tratar la exposicion a radiacion. - Google Patents
Uso de sepiapterina y metabolitos de los mismos para tratar la exposicion a radiacion.Info
- Publication number
- MX2022001535A MX2022001535A MX2022001535A MX2022001535A MX2022001535A MX 2022001535 A MX2022001535 A MX 2022001535A MX 2022001535 A MX2022001535 A MX 2022001535A MX 2022001535 A MX2022001535 A MX 2022001535A MX 2022001535 A MX2022001535 A MX 2022001535A
- Authority
- MX
- Mexico
- Prior art keywords
- sepiapterin
- radiation exposure
- metabolites
- treat radiation
- treat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
La invención proporciona métodos para tratar la exposición a radiación en un sujeto por administrar sepiapterina, tetrahidrobiopterina o dihidrobiopterina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962882937P | 2019-08-05 | 2019-08-05 | |
PCT/US2020/045026 WO2021026247A1 (en) | 2019-08-05 | 2020-08-05 | Use of sepiapterin and metabolites thereof to treat radiation exposure |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022001535A true MX2022001535A (es) | 2022-03-04 |
Family
ID=72148243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022001535A MX2022001535A (es) | 2019-08-05 | 2020-08-05 | Uso de sepiapterina y metabolitos de los mismos para tratar la exposicion a radiacion. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220273661A1 (es) |
EP (1) | EP4009978A1 (es) |
JP (1) | JP2022543655A (es) |
CN (1) | CN114555090A (es) |
AU (1) | AU2020324435A1 (es) |
BR (1) | BR112022002029A2 (es) |
CA (1) | CA3146477A1 (es) |
IL (1) | IL290321A (es) |
MX (1) | MX2022001535A (es) |
WO (1) | WO2021026247A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR122021026889A8 (pt) | 2016-11-29 | 2022-11-22 | Censa Pharmaceuticals Inc | Formas cristalinas de base livre de sepiapterina e de sais dos mesmos, seu método de preparação, composições que as compreendem, uso dos mesmos e método de preparação de uma formulação líquida |
WO2019046849A1 (en) | 2017-09-01 | 2019-03-07 | Censa Pharmaceuticals Inc. | PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF |
US11617752B2 (en) | 2018-05-30 | 2023-04-04 | Ptc Therapeutics Mp, Inc. | Methods for increasing sepiapterin plasma exposure |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5910304A (en) | 1982-12-13 | 1999-06-08 | Texas A&M University System | Low-dose oral administration of interferons |
CA1320905C (en) | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
US6036949A (en) | 1998-03-05 | 2000-03-14 | Amarillo Biosciences, Inc. | Treatment of fibromyalgia with low doses of interferon |
TWI359019B (en) * | 2006-08-14 | 2012-03-01 | Merck Eprova Ag | Use of folates for the prevention and treatment of |
MX2019006207A (es) | 2016-11-29 | 2019-11-18 | Censa Pharmaceuticals Inc | Forma polimorfica de sepiapterina. |
BR122021026889A8 (pt) | 2016-11-29 | 2022-11-22 | Censa Pharmaceuticals Inc | Formas cristalinas de base livre de sepiapterina e de sais dos mesmos, seu método de preparação, composições que as compreendem, uso dos mesmos e método de preparação de uma formulação líquida |
WO2019046849A1 (en) | 2017-09-01 | 2019-03-07 | Censa Pharmaceuticals Inc. | PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF |
JP2021527031A (ja) | 2018-05-30 | 2021-10-11 | ピーティーシー セラピューティクス エムピー,インコーポレイテッド | セピアプテリンの薬学的に許容される塩 |
CN110354133A (zh) * | 2019-08-26 | 2019-10-22 | 鞍山市肿瘤医院 | 四氢生物蝶呤的应用及药物 |
-
2020
- 2020-08-05 CN CN202080069308.5A patent/CN114555090A/zh active Pending
- 2020-08-05 WO PCT/US2020/045026 patent/WO2021026247A1/en active Application Filing
- 2020-08-05 MX MX2022001535A patent/MX2022001535A/es unknown
- 2020-08-05 CA CA3146477A patent/CA3146477A1/en active Pending
- 2020-08-05 US US17/631,995 patent/US20220273661A1/en active Pending
- 2020-08-05 EP EP20758407.9A patent/EP4009978A1/en active Pending
- 2020-08-05 AU AU2020324435A patent/AU2020324435A1/en active Pending
- 2020-08-05 JP JP2022507561A patent/JP2022543655A/ja active Pending
- 2020-08-05 BR BR112022002029A patent/BR112022002029A2/pt unknown
-
2022
- 2022-02-03 IL IL290321A patent/IL290321A/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112022002029A2 (pt) | 2022-06-07 |
US20220273661A1 (en) | 2022-09-01 |
AU2020324435A1 (en) | 2022-02-24 |
WO2021026247A1 (en) | 2021-02-11 |
EP4009978A1 (en) | 2022-06-15 |
IL290321A (en) | 2022-04-01 |
CA3146477A1 (en) | 2021-02-11 |
JP2022543655A (ja) | 2022-10-13 |
CN114555090A (zh) | 2022-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020551923A1 (en) | Methods and compositions for treating cancer | |
MX2022001535A (es) | Uso de sepiapterina y metabolitos de los mismos para tratar la exposicion a radiacion. | |
MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
MX2019013072A (es) | Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1. | |
PH12019501575A1 (en) | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF | |
WO2018022668A3 (en) | NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER | |
MX2021004828A (es) | Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia. | |
MX2019002750A (es) | Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer. | |
MX2019007276A (es) | Composiciones y métodos para mejora o aumento de la producción de ifn tipo i. | |
MX2023001527A (es) | Compuestos con actividad inductora de ferroptosis y metodos de uso de estos. | |
MX2017000408A (es) | Compuestos antiproliferativos y métodos de uso de los mismos. | |
MX2019012464A (es) | Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl. | |
GEP20237519B (en) | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
WO2019040106A3 (en) | COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES | |
CR20200334A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
MX2022007994A (es) | Derivados de arilciclohexilamina y su uso en el tratamiento de trastornos psiquiátricos. | |
MX2019003134A (es) | Terapia de combinacion. | |
BR112017026061A2 (pt) | composto, uso de um composto, e, método de tratamento de uma infecção viral | |
MX2019012465A (es) | Terapia combinada con un conjugado de anticuerpo y farmaco anti-cd25. | |
MY201580A (en) | Use of ezh2 inhibitor combined with btk inhibitor in preparing drug for treating tumor | |
MX2020012979A (es) | Métodos para aumentar la exposición al plasma de sepiapterina. | |
PH12020552059A1 (en) | Dosing regimen for the treatment of pi3k related disorders | |
MY186475A (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
MX2021001612A (es) | Compuestos utiles en terapia del vih. | |
MX2021014905A (es) | Células seguras e invisibles para el sistema inmunitario. |